The molecular basis of CLS lies in loss-of-function mutations in the RSK2 gene (also known as RPS6KA3), which encodes a serine/threonine protein kinase crucial for chromatin design and cellular signaling pathways in humans [82]. The gene discussed is RPS6KA3; the disease is Coffin-Lowry syndrome.